Canaccord Genuity initiated RNA-based drug developer Wave Life Sciences (NASDAQ:WVE) with a Buy recommendation and a $19 per share target on Monday, citing multiple stock-moving catalysts for the company in the near term.

Analyst Whitney Ijem argued that, despite some of